Article Text

Download PDFPDF
CASE REPORT
Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis
  1. Carolin Meinus1,
  2. Carsten Schwarz1,
  3. Beate Mayer2,
  4. J F Roehmel1
  1. 1Division of Cystic Fibrosis, Department of Pediatric Pneumology and Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany
  2. 2Department of Transfusion Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany
  1. Correspondence to Dr Carolin Meinus, carolin.meinus{at}charite.de

Summary

Piperacillin–tazobactam is an antipseudomonal antibiotic frequently used in patients with cystic fibrosis (CF) to treat pulmonary exacerbations. Drug-induced immune haemolytic anaemia is a rare complication during treatment with piperacillin. So far, piperacillin-induced immune haemolytic anaemia (PIHA) is regarded as an acute and severe haemolytic anaemia resulting into life-threatening events. Here we report on a patient with mild PIHA, which did not result in any clinical symptoms or necessity for treatment. To the best of our knowledge, this is the first case report of PIHA without an acute severe haemolytic anaemia. Further research is needed to clarify if this case is a solitary clinical manifestation of PIHA or if mild clinical courses of PIHA might be under-reported. Cases of PIHA have been largely reported in patients with CF. This unequal distribution maybe due to the frequent administration of piperacillin for pulmonary exacerbation in patients with CF or due to CF-related cofactors of yet unknown aetiology.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors CM, CS and JR involved in the management of the patient. BM performed and interpreted the immune-hematologic laboratory tests. All authors contributed to drafting and revision of the manuscript. All authors read and approved the final manuscript.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.